Request Demo
Last update 13 Oct 2026
Omalizumab biosimilar (Zhejiang Hisun)
Last update 13 Oct 2026
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Omalizumab biosimilar, 重组抗IgE人源化单克隆抗体（浙江海正）, HS-632 |
Target |
Action inhibitors |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 81670L
The sequence is quoted from: *****
Sequence Code 143601H
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Omalizumab biosimilar (Zhejiang Hisun)ChiCTR2100047781
Phase i, single-center, randomized, double-blind, parallelity-controlled clinical trial comparing pharmacokinetic and safety comparability of recombinant anti-IgE humanized monoclonal antibody for injection (HS632) with omalizumab (Xolair) after single dose administration in healthy Chinese subjects
NCT04361812
A Multicenter, Randomized, Double-blind, Parallel Controlled，Single-dose Phase I Study Comparing the Pharmacokinetic and Safety Similarities of Recombinant Anti IgE Humanized Monoclonal Antibody (HS632) With Omalizumab a in Healthy Subjects
ChiCTR2000031925
A multicenter, randomized, double-blind, parallel controlled phase I clinical trial comparing the pharmacokinetic and safety similarities of recombinant anti IgE humanized monoclonal antibody for injection(HS632) with Omalizumab (Xolair?) after a single dose administration in Chinese healthy subjects
100 Clinical Results associated with Omalizumab biosimilar (Zhejiang Hisun)
Login to view more data
100 Translational Medicine associated with Omalizumab biosimilar (Zhejiang Hisun)
Login to view more data
100 Patents (Medical) associated with Omalizumab biosimilar (Zhejiang Hisun)
Login to view more data
100 Deals associated with Omalizumab biosimilar (Zhejiang Hisun)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Asthma | Phase 1 | China | 29 Apr 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free